Canopy Immuno-Therapeutics Overview
Canopy is a pre-clinical stage biotech developing a new class of biologics that will allow the elimination of antigen-specific immunity, providing non-immunosuppressive, potentially curing treatments to many dozens of autoimmune, allergic, and other antibody-mediated conditions using its proprietary Reverse-Immunization platform.
Cumulative Funding Raised Over Time ($)
Latest News
Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 2 |
| Investors | 1 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | canopy-biotech.com |
Locations
Haifa, Israel
Photos & Videos
1 item(s)
